Vipragen Biosciences Private Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vipragen Biosciences Private Limited - overview
Established
2012
Location
Bangalore, Karnataka, India
Primary Industry
Biotechnology
About
Based in Bengaluru, India, and founded in 2012, Vipragen Biosciences Private Limited provides CRO with technology integration. The company was founded by Dr. S. Chandrashekaran.
In August 2023, the firm raised an amount of venture funding from returning investor Karnataka Asset Management Company and investor Conscience MFO LLP. The company provides end-to-end regulatory preclinical services to pharmaceutical, biotechnology, veterinary, nutraceutical, and herbal companies, academic institutions, and research organizations for both domestic and international markets. Preclinical services provided by the company adhere to OECD GLP, ISO, WHO, USFDA, USEPA, and Pharmacopoeia (US, India, Japan, Europe, and British) standards and guidelines. The company plans to use the August 2023 funding to enhance its operations and expand into new sectors.
Current Investors
Karnataka Asset Management Company, Conscience MFO LLP
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.vipragen.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Vipragen Biosciences Private Limited - timeline of key events
Vipragen Biosciences Private Limited - financials
| Fiscal Year Ended | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,114,565 | 10,151,855 | 13,721,585 | 18,326,272 | 31,591,119.4 | 26,598,420 | 18,469,506 | 18,970,006 | 28,181,573 | - | - | - |
| % Revenue Growth (YoY) | - | 810.8% | 35.2% | 33.6% | 72.4% | (15.8%) | (30.6%) | 2.7% | 48.6% | - | - | - |
| EBITDA (USD) | (1,659,461) | (1,562,031) | (5,231,825) | (5,627,325) | 5,832,459.6 | 2,611,230.1 | (6,500,488.9) | (4,940,642) | 1,843,001 | - | - | - |
| Operating Income (USD) | (1,808,277) | (3,739,270) | (7,267,365) | (7,735,460) | 3,493,930.4 | 129,763.7 | (9,175,258.7) | (7,866,272) | (1,930,072) | - | - | - |
| Operating Margin | (162.2%) | (36.8%) | (53.0%) | (42.2%) | 11.1% | 0.5% | (49.7%) | (41.5%) | (6.8%) | - | - | - |
| % EBITDA Margin | (148.9%) | (15.4%) | (38.1%) | (30.7%) | 18.5% | 9.8% | (35.2%) | (26.0%) | 6.5% | - | - | - |
| NET Income (USD) | (2,108,964) | (4,017,475) | (8,127,570) | (8,760,834) | 1,543,606.9 | 456,802.2 | (9,793,342.6) | (9,554,803) | (3,748,772) | - | - | - |
| % Net Margin | (189.2%) | (39.6%) | (59.2%) | (47.8%) | 4.9% | 1.7% | (53.0%) | (50.4%) | (13.3%) | - | - | - |
Vipragen Biosciences Private Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.